Pts in Biological Technology

Zymes Omega Solutions Bottles and Launches the World's First Omega-3 Enhanced Water

...hill ( http://www.omegachill.com ). This innovative new water uses Zymes' pts technology to solubilize and stabilize fish-derived omega-3s. The resultin... Zymes Omega Solutions holds the world-wide exclusive rights for the use of pts for omega-3s for food, beverage and dietary supplements. For more informat...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

...ber of Patients Alive (follow up ongoing) 16/81 (20%) Median Overall Survival 14.1 months (0.13-45.9) Number of pts Surviving Greater than or equal to 12 months 54% (43%-64%: 95% CI) Greater than or equal to 18 months(1) 39% (28%-4...

Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology

... Scale-up of Zymes' pts by Albemarle responds to the demand in food, bever...ificant GMP manufacturing capabilities to generate pts in quantities that accelerate its delivery for use...ned GRAS (Generally Recognized as Safe) status for pts following submission to the FDA. In addition to e...

Fufeng Announces 2008 Interim Results With Strong Sign of Recovery

...ecreased by 14.8% to RMB21,547 per tonne in the 1H of 2008. However, the gross profit ratio maintained at high level with a slight adjustment of 1.6 % pts in the 1H of 2008. Talking about the Group's future strategies, Mr. Li said, "It is expected that the market consolidation in MSG market will contin...

REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO

... Oral Presentation "A phase 1 study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)" Day: Sunday, June 1 Session: Developmental Therapeutics: Molecular Therapeutics Time: 10-10:15 a....

Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing

...Presentation "A phase 1 study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)" Day: Sunday, June 1 Session: Developmental Therapeutics: Molecular Therapeutics Time:...

Gala Biotech among companies sold for $3.3 billion

...eeded more focus than Cardinal Health could give it." Cardinal Health, an $81 billion company, announced in late 2006 that it planned to divest the pts segment to focus on healthcare provider customers like hospitals and pharmacies. Cardinal's pharmaceutical technologies and services units, which empl...